Amgen: Repatha Cuts Risk Of First Major Cardiovascular Events By 31% In High-risk Patients Without Known Significant Atherosclerosis

Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary Prevention VESALIUS-CV Subgroup Findings Reinforce Benefit ...
Seeking Alpha

AMGEN'S REPATHA® CUTS RISK OF FIRST MAJOR ADVERSE CARDIOVASCULAR EVENTS BY 25% IN LANDMARK PHASE 3 VESALIUS-CV TRIAL

THOUSAND OAKS, Calif., Nov. 8, 2025 /PRNewswire/ -- Amgen (AMGN) today announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha ® (evolocumab) achieved ...
Seeking Alpha

AMGEN TO PRESENT NEW REPATHA® (EVOLOCUMAB) AND OLPASIRAN DATA AT ACC

--Amgen today announced new Repatha ® combined data from the Phase 3 FOURIER and FOURIER Open Label Extension studies and the Phase 2 OCEAN- DOSE study of investigational olpasiran, an siRNA that ...
Hosted on MSN

Amgen posts Phase 3 trial win for Repatha in major cardiovascular events

Amgen (NASDAQ:AMGN) announced on Thursday that its PCSK9 inhibitor Repatha (evolocumab) reached the primary endpoints in a Phase 3 trial designed to evaluate its effect in reducing major adverse ...

Is Amgen Inc. (AMGN) one of the best pharma stocks to invest in now?

Amgen Inc. (NASDAQ:AMGN) is one of the best pharma stocks to invest in now. Amgen Inc. (NASDAQ:AMGN) announced on March 28 that Repatha® lowered the risk of first major adverse cardiovascular events ...
The Financial

Amgen Announces Repatha Co-Preferred Position on Express Scripts National Formulary

The FINANCIAL — Amgen on October 6 announced that Express Scripts will provide access to Repatha (evolocumab) through its national formulary. “Ensuring access to Repatha for appropriate patients is ...
WGN Radio

AMGEN MAKES REPATHA® AVAILABLE THROUGH AMGENNOW, A DIRECT-TO-PATIENT PROGRAM IN THE U.S.

THOUSAND OAKS, Calif., Oct. 6, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the launch of AmgenNow, a new direct-to-patient program starting with Repatha ® (evolocumab). This follows ...
Yahoo

Amgen to sell cholesterol drug at 60% discount direct to US consumers

LOS ANGELES (Reuters) -Amgen on Monday launched direct-to-consumer U.S. sales of its cholesterol medication Repatha at a discounted cash price, becoming the latest pharmaceutical company responding to ...
Morningstar

AMGEN'S LANDMARK PHASE 3 REPATHA DATA TO BE PRESENTED AS LATE BREAKER AT THE AMERICAN HEART ASSOCIATION SCIENTIFIC SESSIONS 2025

Repatha VESALIUS-CV Trial Met Dual Primary Endpoints Demonstrating Reduction in CV Events in High-Risk Patients Who Have Never Had a Heart Attack or Stroke Real-World Evidence from the Repatha-CE ...

REPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS

Amgen (NASDAQ:AMGN) announced today that Repatha® (evolocumab), when added to statins or other low-density lipoprotein cholesterol (LDL-C)-lowering treatments, reduced the risk of first major adverse ...
Los Angeles Downtown News

AMGEN'S REPATHA® CUTS RISK OF FIRST MAJOR ADVERSE CARDIOVASCULAR EVENTS BY 25% IN LANDMARK PHASE 3 VESALIUS-CV TRIAL

Repatha was first approved in 2015 and has since been used by more than 6.7 million patients globally. 3,4 Earlier this year, the U.S. Food and Drug Administration broadened the approved use of ...